Volume 28, Number 2—February 2022
Research
Invasive Burkholderia cepacia Complex Infections among Persons Who Inject Drugs, Hong Kong, China, 2016–2019
Kristine Shik Luk, Yat-ming Tsang
, Alex Yat-man Ho, Wing-kin To, Ben Kwok-ho Wong, Maureen Mo-lin Wong, and Yiu-chung Wong
, Alex Yat-man Ho, Wing-kin To, Ben Kwok-ho Wong, Maureen Mo-lin Wong, and Yiu-chung Wong
Table 2
Laboratory and microbiological findings, treatments, and outcomes of invasive infections caused by Burkholderia cepacia complex in persons who inject drugs, Hong Kong, China, 2016–2019*
| Variable |
Finding |
| Median leukocytes, × 109 cells/L (range) |
9.2 (3.94–24.7) |
| Median ESR, mm/h (range) |
79.5 (43 to >120) |
| Median CRP, mg/L (range) |
68 (21 to >294) |
| Empirical antimicrobial therapy (no. patients) |
Amoxicillin/clavulanate (10); cloxacillin (3); vancomycin (2); ampicillin, cefoperazone/sulbactam, gentamicin, piperacillin/tazobactam (1) |
| Definitive antimicrobial therapy (no. patients) |
Trimethoprim/sulfamethoxazole (6); ceftazidime (5); levofloxacin (5); meropenem (2); minocycline, piperacillin/tazobactam (1) |
| Median duration of antimicrobial therapy (range), wk |
6 (1–12) |
| Surgery (no. patients) |
Vertebral disk excision (3), incision and drainage (1), spinal fusion† (3), joint arthrotomy (2), excisional arthroplasty (1) |
| Positive culture (no. patients) |
Bone (5), blood† (4), intervertebral disk (3), abscess (2), joint fluid (1) |
| Median length of stay (range), d |
43 (11 – 97) |
| Death (d after first visit) | Patient 3 (124); patient 4 (13) |
*CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. †Patient 2 had a relapse of Burkholderia cepacia complex infective spondylitis 5 mo after receiving meropenem and oral trimethoprim/sulfamethoxazole for 6 wk; spinal fusion was performed during the relapse episode.
Page created: December 02, 2021
Page updated: January 22, 2022
Page reviewed: January 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.